Fortlane Partners advised Exyte

A team of Fortlane Partners advised Exyte GmbH ("Exyte"), a global leader in the design, engineering, and delivery of high-tech facilities, on the acquisition of TTP Group ("TTP"), a leading firm in consulting and engineering for the pharmaceutical and chemical industry in Europe, from funds advised by Robus Capital along with minority shareholders of TTP. The transaction was closed in October 2024.

Through the acquisition of TTP, Exyte creates a strong partner for the booming European biotechnology and pharmaceutical industry. TTP is a specialized and a trusted partner for blue-chip clients in the biotech, pharma and chemical industries in Europe. Through its two operational brands 'Pharmaplan' and 'Triplan', the company covers the entire service spectrum from Engineering to Procurement, Construction Management, and Validation. Exyte will combine TTP’s operations with its own Biopharma and Life Sciences activities in Europe.

Fortlane Partners acted as sole and exclusive M&A buy-side advisor to Exyte. This transaction demonstrates our ability to achieve outperforming results for our clients and underscores Fortlane Partners' expertise in advising high-tech engineering services clients.

About Exyte
Exyte is a global leader in the design, engineering, and delivery of ultra-clean and sustainable facilities for high-tech industries. With cutting-edge expertise developed over more than a century, the company serves clients in the sophisticated markets of semiconductors, battery cells, pharmaceuticals, biotechnology, and data centers. Exyte offers a full range of services from consulting to managing the implementation of built complete solutions with the highest standards in safety and quality to its customers worldwide. Exyte creates a better future by enabling key industries to enhance the quality of modern life. In 2023, the company generated sales of €7.1 billion with around 9.900 employees worldwide.

About TTP Group
TTP Group is a corporate group specializing in consulting and engineering services for the process industry. With more than 1,000 employees working under the operational brands Pharmaplan and Triplan, the company operates at 27 locations in Germany, Switzerland, Austria, France and Belgium. Pharmaplan covers the entire value chain of pharmaceutical engineering, from consulting to the execution of EPCM projects and upgrades, qualification and validation as well as local site support. Triplan, as a leading engineering partner for the chemical industry, provides the technical development of new construction, renovation projects, and the optimization of existing facilities. With its two strong brands, established for over 50 years, the TTP Group is considered one of the leading engineering service providers in Europe.

Transaction Team:
Christian Muthler
Managing Director
Email

Maximilian Bergold
Director

Markus Rosen
Director

Matthias Friedl, CFA
Associate

Christoph Pfeifer
Analyst